Skip to main content

Table 2 Links between genetic alterations and drug response

From: Patient-derived organoid (PDO) platforms to facilitate clinical decision making

Cell type Paper Cell characteristics Drug sensitivities
Breast cancer organoids [28] Overexpression of HER2 Sensitive to drugs blocking HER signalinga
Breast cancer organoids [28] High BRCA1/2 signature Sensitive to the poly(ADP-ribose) polymerase inhibitors: olaparib and niraparib
Colorectal cancer organoids [29, 47] Loss of function mutations in the tumor suppressor TP53 Resistant to nutlin-3a
Colorectal cancer organoids [47] Truncating mutation in RNF43 (a recessive cancer gene encoding a negative regulator of WNT pathway) Highly sensitive to the WNT secretion inhibitor IWP2
Liver cancer organoids [6] CTNNB1 mutants
Wnt-dependent tumor
KRAS mutant
Lines that are insensitive to BRAF and/or MEK inhibitors (dabrafenib and drametinib)
Resistant to the porcupine inhibitor LGK974
Sensitive to the porcupine inhibitor LGK974
Resistant to the EGFR family inhibitor AZD8931
Organoid formation inhibited by SCH772984
Liver cancer organoids transplanted into mice [6] Lines that are insensitive to BRAF and/or MEK inhibitors (dabrafenib and drametinib) Significant reduction in tumor growth by SCH772984
Prostate cancer organoids [27] PTEN loss and PIK3R1 mutation Sensitive to both everolimus and BKM-120
  1. aOften but not always